Evidence map›Paper›PMID 37138827›Full record

ArticleJAAD international2023

Evolving teledermatology policy and reimbursement landscape in the United States.

Stephanie K Lin, Annika M Deitermann, Christopher J Miller, Amit Garg, Jonathan Ungar, Harrison P Nguyen

Abstract read
In one paragraph

Article in JAAD international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Regulation and Compliance in Telemedicine: Viewpoint.Journal of medical Internet research · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephanie K LinDepartment of Dermatology, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Annika M DeitermannUniversity of Minnesota Medical School, Minneapolis, Minnesota.
Christopher J MillerDepartment of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Amit GargDepartment of Dermatology, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Jonathan UngarWaldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Harrison P NguyenDepartment of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Policymakers and payers are reevaluating the temporary telehealth flexibilities granted during the COVID-19 public health emergency, which will shape future teledermatology utilization. Objective: To summarize the recently expanded telehealth flexibilities in the United States, projected changes, and corresponding implications for dermatologists. Methods: Narrative review of the literature, United States policies and regulations, and white paper reports. Results: Key telehealth flexibilities included expansion of payment parity, relaxation of originating site requirements, loosening of state licensure requirements, and HIPAA (Health Insurance Portability and Accountability Act of 1996) enforcement discretion. These changes enabled widespread accessibility and adoption of teledermatology, which enhanced high-quality and cost-effective dermatologic care. Most waivers will end 151 days following the end of the public health emergency declaration. Notably, asynchronous telehealth was not included in the reimbursement expansion. Limitations: Only policies and regulations through December 2022 are included. Conclusion: It will be important for the field of dermatology to stay abreast of the upcoming changes in telemedicine policies and reimbursement, to demonstrate teledermatology's value through evidence-based studies and to advocate for enduring policies that will promote the accessibility of teledermatology for patients.

Indexed as

COVID-19digital healthhealth policylive-interactivereimbursementstore-and-forwardteledermatologytelehealthtelemedicine

Identifiers

PMID37138827
PMCPMC10149399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.